Association of twelve polymorphisms in three onco-lncRNA genes with hepatocellular cancer risk and prognosis: A case-control study

Table 4 Univariate proportional hazard analysis stratified by host characteristics for the association of lncRNA polymorphisms and hepatocellular cancer n (%)

Gene	SNP	Stratified	Stratified factors	Genotype	HCC	Death	MST (M)	P value	Hazard ratio (95%CI)
HOTTIP	rs3807598				n = 136
		HBV	Positive	CC	30 (22.06)	12	90.0		1 (reference)
				CG	73 (53.68)	23	90.1b	0.391	0.74 (0.37-1.48)
				GG	33 (24.26)	11	64.1b	0.680	0.84 (0.37-1.91)
					n = 31
			Negative	CC	10 (32.26)	7	21.0		1 (reference)
				CG	13 (41.94)	4	41.8b	0.374	0.60 (0.16-1.97)
				GG	8 (25.80)	1	70.3b	0.049	0.12 (0.02-0.99)
					n = 285
MALAT1	rs591291				n = 286
		Gender	Male	CC	98 (34.27)	39	48.0		1 (reference)
				TC	146 (51.05)	56	56.0	0.865	0.97 (0.64-1.45)
				TT	42 (14.68)	19	47.0	0.678	1.12 (0.65-1.94)
					n = 64
			Female	CC	22 (34.38)	13	32.0		1 (reference)
				TC	37 (57.81)	9	56.0	0.022	0.37 (0.16-0.87)
				TT	5 (7.81)	0	NA	0.286	0.04 (0.00-16.09)
					n = 139
		HBV	Positive	CC	54 (38.85)	18	69.0		1 (reference)
				TC	69 (49.64)	21	92.1b	0.816	0.93 (0.49-1.74)
				TT	16 (11.51)	7	90.0	0.965	0.98 (0.41-2.35)
					n = 31
			Negative	CC	8 (25.81)	5	6.0		1 (reference)
				TC	16 (51.61)	4	27.0	0.042	0.25 (0.07-0.95)
				TT	7 (22.58)	3	21.0	0.215	0.40 (0.09-1.71)

HR: Hazard rate; MST: Median survival time (months); NA: Not available.